Vator Securities advises Scandion Oncology on 60 MSEK Rights Issue
Scandion is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.
Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.
read more
Vator Securities acts as Bookrunner in SciBase 33 MSEK Directed Issue and 15 MSEK Rights Issue
SciBase is a global medical technology company specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to increase diagnostic accuracy and ensure the prevention of skin diseases.
SciBase’s commitment is to minimize patient suffering, enable physicians to improve and save lives through rapid detection and intervention, and reduce healthcare costs.
read more
Vator Securities advises Magle Chemoswed Holding in connection with its public offer to the shareholders of Amniotics
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas.
Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products.
read more
Vator Securities acts as Sole Bookrunner in LifeClean International 16 MSEK Directed Issue
LifeClean International offers sustainable disinfection, sanitation and cleaning solutions that address several of our biggest challenges, such as antimicrobial resistance, contamination and PFAS pollution. Among other things, LifeClean is behind the world’s first climate-neutral chemical production, the world’s richest detergent and a unique, patented and more environmentally friendly chemical formula based on chlorine dioxide.
The chemical technology is the basis for a proven effective method for PFAS sanitation and is also verified as a spore-, fungus-, biofilm-, bacteria- and virus-killing surface disinfection. The Company operates two production facilities in Sweden, certified according to ISO 13485, ISO 14001 and ISO 9001.
read more
60 MSEK | Q2 2024
48 MSEK | Q2 2024
M&A | Q1 2024
16 MSEK | Q1 2024
